NASDAQ:ZURA

Zura Bio Class A Ordinary Shares Stock News

etoro logo Buy ZURA
*Your capital is at risk
$5.43
-0.110 (-1.99%)
At Close: Jul 31, 2026
Shares of Zura Bio Limited (NASDAQ: ZURA - Get Free Report) have received an average rating of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One equitie
Zura Bio Limited (NASDAQ: ZURA - Get Free Report)'s share price rose 5.3% during trading on Friday. The company traded as high as $5.52 and last traded at $5.5280. 150,021 shares were traded during tr
On Wednesday, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating, citing the potential of its lead candidate, tibulizumab, to deliver differentiated efficacy
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives o
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfull
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives o
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives o
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfu
Zura Bio Limited (NASDAQ: ZURA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat.com reports. One analy
Zura Bio Limited (NASDAQ: ZURA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated t
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningful
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medi
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE